Skip to content
FIND A HEALTH VALLEY ACTOR

BioLizard chooses Biopôle for its Swiss subsidiary

BioLizard

BioLizard is a Belgian bioinformatics, data analytics and data management service and consulting company heading digital transformation in the life sciences industry.     Liesbeth Ceelen, PhD, CEO of BioLizard, said: “We aim to meet the need for expertise and tools for digital transformation of biotech companies, including for AI-enabled, user-friendly software and data infrastructure.…

Read More

Oryl Photonics raises CHF 830,000 in seed funding

Oryl Photonics

The Vaud-based startup announces the successful conclusion of a CHF 830,000 seed fundraising. The round is backed by Swiss investors, including CADFEM International AG, S2S Ventures and several business angels.     This is a significant achievement for Oryl Photonics, a company pioneering the development of highly efficient solubility measurement for pharmaceutical and life science…

Read More

CSEM Inventor Award granted to spaceCoder

CSEM Inventor Award

Shedding Light on Precision: CSEM spaceCoder technology is a game changer in the field of precision measurement     In the realm of scientific innovation, where light illuminates, shadows also cast opportunities for advancement. Researchers at CSEM (Centre Suisse d’Electronique et de Microtechnique) have ingeniously harnessed this principle with their groundbreaking “spaceCoder” technology, heralding a…

Read More

Successful € 5 Million Capital Increase for GeNeuro

GeNeuro

GeNeuro, a Geneva-based biopharmaceutical company focusing on treatments for neurodegenerative and autoimmune diseases, including multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and severe neuropsychiatric consequences of COVID-19 (post-COVID), has successfully completed a €5 million capital increase.     The increase involved a private placement of 4,666,901 new GeNeuro ordinary bearer shares for specialized and strategic…

Read More

Nicolas Durand appointed Director of the Campus Biotech Foundation in Geneva

Nicolas Durand 2

Dr Nicolas Durand will step down from his CEO role at Abionic on 29 February to be at the steering wheel of the innovation centre from 1 March 2024     The Foundation Campus Biotech announced the appointment of its new Director, Dr Nicolas Durand. “With an extensive background in nanotechnologies applied to life sciences,…

Read More

CHF 870 Million invested in Swiss medtech and biotech companies

Swiss Venture Capital Report

In the midst of an unfavourable environment, the life sciences’ sector continues to attract investors in Switzerland according to the Swiss Venture Capital Report 2024.     In 2023, the downturn on the global venture capital market reached Switzerland. Swiss startups received a total of CHF 2.6 Billion last year, 35% less than in 2022.…

Read More

Debiopharm and TransCode Therapeutics Collaborate to Develop Targeted Nucleic Acid Therapeutics for Cancer

Debiopharm

TransCode Therapeutics is a RNA oncology company based in the United States committed to more effectively treating cancer using RNA therapeutics. Debiopharm, a privately-owned Swiss-based, global biopharmaceutical company, aims to establish tomorrow’s standard-of-care to cure cancer and infectious diseases.     The collaboration will explore combining TransCode’s proprietary TTX delivery platform with Debiopharm’s expertise in…

Read More

Vaud: a CHF 90 Million plan to tackle the shortage of healthcare staff

InvestPro Programme Vaud

The Vaud State Council has drawn up a CHF 90 Million “far-reaching plan” to meet the challenges presented by the shortage of healthcare and nursing staff: the InvestPro programme will be based on training, promotion of the professions in the field and retention.     Demographic change, an ageing population and an increase in chronic…

Read More

Transmutex raises CHF 20 Million

Transmutex

The Geneva-based company, founded in 2019, has secured new funding to further develop its research into safer, cleaner and cheaper nuclear power generation. The technology could also have healthcare applications.     Geneva-based nuclear engineering company Transmutex has secured CHF 20 Million in financing from New York-based venture capital funds Union Square Ventures and Steel…

Read More

Pfizer Research Prize: 3 Researchers From The Swiss Health Valley Awarded

Pfizer Foundation Prize

13 young researchers from Fribourg, Geneva, Basel, Bern, and Zurich have won a 2024 Pfizer Research Award.   Since 1992, Pfizer Prize for Research has been awarded annually to young scientists conducting research at Swiss research institutes or hospitals. The award, is aimed at outstanding and pioneering contributions in pure and clinical research. Each awarded…

Read More